The dose-dependent decrease in plasma aldosterone at doses ≥1.5 mg and lack of effect on cortisol demonstrate the selective blockade of aldosterone synthase and support continued study in ongoing phase 2 clinical trials evaluating the efficacy and safety of baxdrostat for treatment-resistant or uncontrolled hypertension and primary aldosteronism. Here, CYP11B2 is linked to Hypertension.